{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T01:09:49Z","timestamp":1791853789638,"version":"4.3.4"},"reference-count":62,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2023,6,13]],"date-time":"2023-06-13T00:00:00Z","timestamp":1686614400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2023,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Tildrakizumab (TIL) is an interleukin (IL)\u201023p19 inhibitor for the treatment of moderate\u2010to\u2010severe plaque psoriasis with long\u2010term efficacy and safety demonstrated in Phase III trials. Studies conducted in conditions closer to clinical practice are needed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objectives<\/jats:title><jats:p>The TRIBUTE study (open\u2010label, Phase IV) assessed the efficacy and impact on health\u2010related quality of life (HRQoL) of TIL 100\u2009mg in adult moderate\u2010to\u2010severe psoriasis patients (na\u00efve to IL\u201023\/Th17 pathway inhibitors) in conditions similar to clinical practice.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Key efficacy measure was Psoriasis Area Severity Index (PASI). HRQoL was evaluated using the Dermatology Life Quality Index (DLQI) and Skindex\u201016. Additional patient\u2010reported outcomes included Pain\u2010, Pruritus\u2010 and Scaling\u2010Numerical Rating Scale (NRS), Medical Outcome Study (MOS)\u2010Sleep, Work Productivity and Activity Impairment (WPAI), Patient Benefit Index (PBI) and Treatment Satisfaction Questionnaire for Medication (TSQM).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and seventy\u2010seven patients were enrolled (six patients did not complete the study). After 24\u2009weeks, the proportion of patients achieving PASI scores\u2009\u2264\u20093, PASI 75, PASI 90 and DLQI 0\/1 was 88.4%, 92.5%, 74.0% and 70.4%, respectively. Skindex\u201016 overall score improved (mean absolute change from baseline, MACB [95%CI]: \u221253.3 [\u221258.1, \u221248.5]). Significant benefits (MACB [95%CI]) were found on pruritus\u2010, pain\u2010 and scaling\u2010NRS scores (\u22125.7 [\u22126.1, \u22125.2], \u22123.5 [\u22124.1, \u22123.0] and \u22125.7 [\u22126.2, \u22125.2], respectively), MOS\u2010Sleep (\u221210.4 [\u221213.3, \u22127.4] Sleep problems Index II) and WPAI (\u221236.4 [\u221242.6, \u221230.2] activity impairment, \u221228.2 [\u221234.7, \u221221.7] productivity loss, \u221227.0 [\u221232.9, \u221221.1] presenteeism and \u22126.8 [\u221212.1, \u22121.5] absenteeism). 82.7% of patients reported PBI\u2009\u2265\u20093 and the mean (SD) global TSQM score was high (80.5 [18.5]). Only one serious treatment\u2010emergent adverse event was reported (not\u2010related to TIL).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>TIL 100\u2009mg treatment after 24\u2009weeks in conditions close to real clinical practice showed a quick and high improvement in psoriasis signs and HRQoL. Patient reported improvements in sleep outcomes and work productivity, relevant benefits and high treatment satisfaction. The safety profile was favourable and consistent with Phase III trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/jdv.19229","type":"journal-article","created":{"date-parts":[[2023,5,29]],"date-time":"2023-05-29T07:40:04Z","timestamp":1685346004000},"page":"2004-2015","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Tildrakizumab improves high burden skin symptoms, impaired sleep and quality of life of moderate\u2010to\u2010severe plaque psoriasis patients in conditions close to clinical practice"],"prefix":"10.1111","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9697-2557","authenticated-orcid":false,"given":"Antonio","family":"Costanzo","sequence":"first","affiliation":[{"name":"Section of Dermatology, Department of Biomedical Sciences Humanitas University  Milan Italy"},{"name":"Dermatology Unit IRCCS Humanitas Research Hospital, Rozzano  Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1187-1341","authenticated-orcid":false,"given":"Mar","family":"Llamas\u2010Velasco","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de la Princesa  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Section of Dermatology, Department of Clinical Medicine and Surgery University of Naples Federico II  Naples Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo","family":"Cuccia","sequence":"additional","affiliation":[{"name":"Unit of Dermatology San Donato Hospital  Arezzo Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4604-0724","authenticated-orcid":false,"given":"Raquel","family":"Rivera\u2010Diaz","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario 12 de Octubre, Universidad Complutense  Madrid Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristian","family":"Gaarn\u00a0Du\u00a0Jardin","sequence":"additional","affiliation":[{"name":"Almirall R&amp;D  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Kasujee","sequence":"additional","affiliation":[{"name":"Almirall R&amp;D  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6083-0952","authenticated-orcid":false,"given":"Llu\u00eds","family":"Puig","sequence":"additional","affiliation":[{"name":"Department of Dermatology IIB SANTPAU, Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jos\u00e9 Manuel","family":"Carrascosa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Germans Trias i Pujol  Badalona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,13]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2012.339"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7"},{"key":"e_1_2_10_5_1","unstructured":"European medicines agency. Ilumetri [Internet].2018[cited 2021 Dec 16]. Available from:https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/ilumetri"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19866"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.0183"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15878"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1159\/000519924"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04000.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.12000"},{"issue":"2","key":"e_1_2_10_13_1","first-page":"183","article-title":"Understanding the relationship between pruritus severity and work productivity in patients with moderate\u2010to\u2010severe psoriasis: sleep problems are a mediating factor","volume":"15","author":"Kimball AB","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S4465"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67763-X"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13065"},{"issue":"6","key":"e_1_2_10_17_1","first-page":"42","article-title":"The disruptiveness of itchiness from psoriasis: a qualitative study of the impact of a single symptom on quality of life","volume":"14","author":"Taliercio VL","year":"2021","journal-title":"J Clin Aesthet Dermatol"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2017.07.002"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14114"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2004.04.012"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2008.08832.x"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18435"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2642"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2011.11.003"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12761"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2004.07.006"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpain.2006.05.002"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15098"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00403-012-1256-y"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16431"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-020-00475-8"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14676"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15226"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1747590"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15489"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2022.2081655"},{"key":"e_1_2_10_37_1","first-page":"1","article-title":"Treatment of moderate\u2010to\u2010severe plaque psoriasis with tildrakizumab in the real\u2010life setting","volume":"10","author":"Burlando M","year":"2021","journal-title":"Drugs Context"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072170"},{"issue":"1","key":"e_1_2_10_39_1","first-page":"406","article-title":"Real\u2010world effectiveness and safety of Guselkumab for the treatment of psoriasis: a 6\u2010month prospective study in a series of psoriatic patients","volume":"25","author":"Malara G","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18218"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-021-00556-2"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16128"},{"issue":"2","key":"e_1_2_10_43_1","article-title":"Effectiveness and safety of guselkumab for the treatment of psoriasis in real\u2010world settings at 24\u2009weeks: a retrospective, observational, multicentre study by the Spanish psoriasis group","volume":"35","author":"Alc\u00e1zar E","year":"2022","journal-title":"Dermatol Ther"},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S364640"},{"key":"e_1_2_10_45_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3417"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.20765"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1221"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-7-62"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15450"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-1920"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2009.07.003"},{"key":"e_1_2_10_52_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2021.674460"},{"key":"e_1_2_10_53_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16702"},{"key":"e_1_2_10_54_1","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S288557"},{"key":"e_1_2_10_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smrv.2015.09.003"},{"key":"e_1_2_10_56_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040664"},{"key":"e_1_2_10_57_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.12207"},{"key":"e_1_2_10_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14464"},{"key":"e_1_2_10_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.049"},{"key":"e_1_2_10_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb05019.x"},{"key":"e_1_2_10_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2007.07.023"},{"issue":"7","key":"e_1_2_10_62_1","first-page":"606","article-title":"Absolute versus relative psoriasis area and severity index in clinical practice","volume":"110","author":"Del Alc\u00e1zar VE","year":"2019","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"e_1_2_10_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2022.01.024"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.19229","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T13:14:53Z","timestamp":1711026893000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.19229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,13]]},"references-count":62,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["10.1111\/jdv.19229"],"URL":"https:\/\/doi.org\/10.1111\/jdv.19229","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,13]]},"assertion":[{"value":"2022-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-04-20","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-13","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}